Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting

This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.

Study Type:        Interventional

Study Design:        

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:        Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)                                                 

Condition: 

Hepatosplenic T-Cell Lymphoma
NK-Cell Lymphoma, Unclassifiable
Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative
Recurrent Adult T-Cell Leukemia/Lymphoma
Recurrent Anaplastic Large Cell Lymphoma
Recurrent Angioimmunoblastic T-cell Lymphoma
Recurrent Enteropathy-Associated T-Cell Lymphoma
Recurrent Mycosis Fungoides
Refractory Adult T-Cell Leukemia/Lymphoma
Refractory Anaplastic Large Cell Lymphoma
Refractory Angioimmunoblastic T-cell Lymphoma
Refractory Enteropathy-Associated T-Cell Lymphoma
Refractory Mycosis Fungoides
Refractory Nasal Type Extranodal NK/T-Cell Lymphoma
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
                                      

Intervention:  

Drug: Nivolumab   
Other: Laboratory Biomarker Analysis                           

Phase:  Phase 2

External Link:  https://clinicaltrials.gov/ct2/show/NCT03075553